Zhengbang Technology lost 7.64 billion yuan in the first three quarters, and was filed for bankruptcy and reorganization by its suppliers. The stock price fell 60% this year.
How to accelerate the implementation of biomedicine from R&D innovation to commercial implementation? This must be done so that it can be achieved naturally
Bank of America Securities released a research report saying that it gave China Pacific Insurance (02601.HK) a "buy" rating, and the target price was HK$27.7 due to its low valuation.